<DOC>
	<DOCNO>NCT00493467</DOCNO>
	<brief_summary>The goal clinical research study find give ( Rituxan ) rituximab 90Y ( ibritumomab tiuxetan ) ( 90 Y ZevalinÂ® ) may effective treat low-grade lymphoma . The safety combination treatment also study .</brief_summary>
	<brief_title>Zevalin ( Ibritumomab Tiuxetan ) Early Stage Indolent Lymphomas</brief_title>
	<detailed_description>90 Y Zevalin rituximab design attach lymphoma cell , cause die . Before start treatment study , `` screening test . '' These test help doctor decide eligible take part study . You physical exam . Blood ( 2 3 teaspoon ) urine collect routine test . You chest x-ray computerized tomography ( CT ) scan neck , chest , abdomen ( stomach area ) , pelvis . A PET scan also recommend . A PET ( Positron Emission Tomography ) scan medical technique monitor activity brain organ track movement special radioactive solution body . The radioactive solution either inhaled mist inject vein . The radioactive solution usually make simple sugar radioactive particle attach . After solution inject vein inhale , PET scanner take picture radioactive solution move body collect various organ . By watch solution travel body study solution collect , researcher learn extent disease certain organ body . You electrocardiogram ( ECG -- test measure electrical activity heart ) . You bone marrow aspirate biopsy perform . To collect bone marrow aspirate biopsy , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . Women able child must negative blood urine pregnancy test . If find eligible take part study , give diphenhydramine ( Benadryl ) vein take acetaminophen ( Tylenol ) mouth dose rituximab . This do help decrease risk develop side effect rituximab . You receive 1 dose rituximab vein 4-6 hour Day 1 treatment . After treatment rituximab , give 111 In Zevalin ( radioactive agent bind rituximab help image exam ) , vein 10 minute . This researcher use special camera see drug body . You image perform ( camera , like x-ray ) either Day 2 3 . On Day 8 ( 7 day first dose rituximab ) receive second dose rituximab . You also give Benadryl , Tylenol , 90Y Zevalin manner Day 1 . If experience intolerable side effect study , may remove study . Your treatment study end Day 8 . You return follow-up test 4 year . Blood ( 2 tablespoon ) draw weekly first 3 month . Blood ( 2 tablespoon time ) also draw month 6 9 first year , every 6 month second , third , fourth year . You may also CT scan , PET scan ( recommend ) , x-rays , bone marrow biopsy aspirate perform , doctor think necessary . Your participation study end 4 year . This investigational study . 90 Y Zevalin rituximab FDA approve commercially available . Their use study investigational . Up 36 patient take part multicenter study . Up 36 patient enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . New diagnosis lowgrade indolent lymphoma Stage III . Patients multiple skin lesion eligible provide skin site involvement . 2 . Histology include Indolent cluster differentiation antigen 20 ( CD20 ) + lymphomas include : Follicular lymphoma , Extranodal marginal lymphoma MALT type , Nodal Marginal zone Bcell lymphoma ( +/ monocytoid cell ) , Splenic marginal Bcell lymphoma ( +/ villous lymphocyte ) . 3 . Signed Informed Consent . 4 . Age &gt; /= 18 year . 5 . Prestudy Zubrod performance status 0 , 1 , 2 . 6 . Acceptable hematologic status within two week prior patient registration , include : absolute neutrophil count ( [ segment neutrophil + band ] x total WBC ) &gt; /= 1 , 500/mm^3 , total lymphocyte count &lt; /= 5,000/mm^3 platelet count &gt; /= 100,000/mm^3 . 7 . Female patient pregnant lactate . 8 . Men woman reproductive potential following accept birth control method ( determine treat physician , however abstinence acceptable method ) . 9 . Patients determine &lt; 25 % bone marrow involvement lymphoma within six week registration ( define measurement bone marrow aspirate biopsy ) . 10 . Patient least one lesion measure &gt; /= 1.5 cm single dimension . Measurable cutaneous lesion allow . 1 . Presence central nervous system ( CNS ) lymphoma . 2 . Patients HIV AIDSrelated lymphoma . 3 . Patients pleural effusion . 4 . Patients abnormal liver function : total bilirubin &gt; 2.0 mg/dL . 5 . Patients abnormal renal function : serum creatinine &gt; 2.0 mg/dL . 6 . Patients receive prior external beam radiation therapy &gt; 25 % active bone marrow ( involved field regional ) . 7 . Impaired bone marrow reserve indicate &lt; 15 % bone marrow cellularity 8 . Serious nonmalignant disease infection , opinion investigator and/or sponsor , would compromise protocol objective . 9 . Major surgery , diagnostic surgery , within four week . 10 . Evidence transformation late biopsy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Indolent Lymphomas</keyword>
	<keyword>Ibritumomab Tiuxetan</keyword>
	<keyword>Zevalin</keyword>
</DOC>